5F-CUMYL-P7AICA

In today's world, 5F-CUMYL-P7AICA is a topic that sparks great interest and debate. Whether in academic, professional or personal fields, 5F-CUMYL-P7AICA has become a relevant and topical topic. From its origins to its impact on today's society, 5F-CUMYL-P7AICA has generated a wide range of opinions and perspectives. In this article, we will explore various aspects related to 5F-CUMYL-P7AICA, from its historical background to its influence on popular culture. Additionally, we will discuss the implications and challenges that 5F-CUMYL-P7AICA represents in different contexts, as well as possible solutions and approaches to address them. Join us on this tour through the fascinating world of 5F-CUMYL-P7AICA!

5F-CUMYL-P7AICA
Legal status
Legal status
Identifiers
  • 1-(5-Fluoropentyl)-N-(2-phenylpropan-2-yl)pyrrolopyridine-3-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC22H26FN3O
Molar mass367.468 g·mol−1
3D model (JSmol)
  • FCCCCCn1cc(c3cccnc13)C(=O)NC(C)(C)c2ccccc2
  • InChI=1S/C22H26FN3O/c1-22(2,17-10-5-3-6-11-17)25-21(27)19-16-26(15-8-4-7-13-23)20-18(19)12-9-14-24-20/h3,5-6,9-12,14,16H,4,7-8,13,15H2,1-2H3,(H,25,27)
  • Key:MXJYOUMYJGNQEY-UHFFFAOYSA-N

5F-CUMYL-P7AICA (also known as CUMYL-5F-P7AICA or SGT-263) is a pyrrolopyridine-3-carboxamide based synthetic cannabinoid that has been sold as a designer drug. It was first identified by the EMCDDA in February 2015.

See also

References

  1. ^ Ernst L, Brandhorst K, Papke U, Altrogge A, Zodel S, Langer N, Beuerle T (August 2017). "Identification and quantification of synthetic cannabinoids in 'spice-like' herbal mixtures: Update of the German situation in early 2017". Forensic Science International. 277: 51–58. doi:10.1016/j.forsciint.2017.05.019. PMID 28601726.
  2. ^ Staeheli SN, Poetzsch M, Veloso VP, Bovens M, Bissig C, Steuer AE, Kraemer T (January 2018). "In vitro metabolism of the synthetic cannabinoids CUMYL-PINACA, 5F-CUMYL-PINACA, CUMYL-4CN-BINACA, 5F-CUMYL-P7AICA and CUMYL-4CN-B7AICA". Drug Testing and Analysis. 10 (1): 148–157. doi:10.1002/dta.2298. PMID 28885775.
  3. ^ Bovens M, Bissig C, Staeheli SN, Poetzsch M, Pfeiffer B, Kraemer T (December 2017). "Structural characterization of the new synthetic cannabinoids CUMYL-PINACA, 5F-CUMYL-PINACA, CUMYL-4CN-BINACA, 5F-CUMYL-P7AICA and CUMYL-4CN-B7AICA". Forensic Science International. 281: 98–105. doi:10.1016/j.forsciint.2017.10.020. PMID 29125990.
  4. ^ Banister SD, Adams A, Kevin RC, Macdonald C, Glass M, Boyd R, Connor M, McGregor IS, Havel CM, Bright SJ, Ventura Vilamala M, Gil Lladanosa C, Barratt MJ, Gerona RR (August 2018). "Synthesis and pharmacology of new psychoactive substance 5F-CUMYL-P7AICA, a scaffold-hopping analog of synthetic cannabinoid receptor agonists 5F-CUMYL-PICA and 5F-CUMYL-PINACA". Drug Testing and Analysis. 11 (2): 279–291. doi:10.1002/dta.2491. hdl:1959.4/unsworks_58933. PMID 30151911. S2CID 52100276.
  5. ^ Walle N, Nordmeier F, Doerr AA, Peters B, Laschke MW, Menger MD, Schmidt PH, Meyer MR, Schaefer N (July 2020). "Comparison of in vitro and in vivo models for the elucidation of metabolic patterns of 7-azaindole-derived synthetic cannabinoids exemplified using cumyl-5F-P7AICA". Drug Testing and Analysis. 13 (1): 74–90. doi:10.1002/dta.2899. PMID 32678962.
  6. ^ Gatch MB, Tourigny A, Shetty RA, Forster MJ (February 2021). "Behavioral pharmacology of five novel synthetic cannabinoids". Behavioural Pharmacology. 33 (2&3): 175–183. doi:10.1097/FBP.0000000000000618. PMC 8364570. PMID 33595956.
  7. ^ "Annual Report on the implementation of Council Decision 2005/387/JHA" (PDF). Europol. 2015.
  8. ^ a b c Cannaert A, Sparkes E, Pike E, Luo JL, Fang A, Kevin RC, Ellison R, Gerona R, Banister SD, Stove CP (2020). "Synthesis and in Vitro Cannabinoid Receptor 1 Activity of Recently Detected Synthetic Cannabinoids 4F-MDMB-BICA, 5F-MPP-PICA, MMB-4en-PICA, CUMYL-CBMICA, ADB-BINACA, APP-BINACA, 4F-MDMB-BINACA, MDMB-4en-PINACA, A-CHMINACA, 5F-AB-P7AICA, 5F-MDMB-P7AICA, and 5F-AP7AICA". ACS Chemical Neuroscience. 11 (24): 4434–4446. doi:10.1021/acschemneuro.0c00644. PMID 33253529. S2CID 227246346.